Citations 3
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
D’Amico, Thomas A., Bentrem, David J., Cooke, David J. , Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Farjah, Farhood , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Keswani, Rajesh N. , Kleinberg, Lawrence , Lacy, Jill , Licciardi, Frank, Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael, Miller, Aaron , Mukherjee, Sarbajit , Mulcahy, Mary F. , Poultsides, George A. , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Wang, Hanlin L. , Wiesner, Georgia L. , Willett, Christopher G. , Yakoub, Danny , Yoon, Harry H. , McMillian, Nicole R., Pluchino, Lenora A. , Yoon, Harry, Ajani, Jaffer A. , Cooke, David, Gerdes, Hans, Gibson, Michael K. , Kim, Sunnie S. Y. , Klempner, Samuel J. , Miller, Aaron, Outlaw, Darryl Alan , Perry, Kyle A. , Pimiento, José M.
Journal of the National Comprehensive Cancer Network | April 4, 2023 | Volume: 21 | Issue: 4 | Pages: 393-422
Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In contrast to esophageal adenocarcinoma, which usually affects the lower esophagus, esophageal SCC is more likely to localize at or higher than the tracheal bifurcation. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability status, and the expression of programmed death-ligand 1, has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, ipilimumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with locally advanced esophageal or esophagogastric junction cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on the management of recurrent or metastatic disease.
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
D’Amico, Thomas A., Bentrem, David J. , Cooke, David T. , Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Keswani, Rajesh N. , Kleinberg, Lawrence , Lacy, Jill , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Park, Haeseong , Poultsides, George A. , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Wang, Hanlin L. , Wiesner, Georgia L. , Willett, Christopher G. , Yakoub, Danny , Yoon, Harry H. , McMillian, Nicole R., Pluchino, Lenora A. , Yoon, Harry, Ajani, Jaffer A. , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Kim, Sunnie S. Y. , Klempner, Samuel J. , Outlaw, Darryl Alan , Perry, Kyle A. , Pimiento, José M.
Journal of the National Comprehensive Cancer Network | February 7, 2022 | Volume: 20 | Issue: 2 | Pages: 167-192
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed death-ligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Denlinger, Crystal S. , Enzinger, Peter C. , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Glasgow, Robert E. , Hayman, James A. , Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Jaroszewski, Dawn E. , Johung, Kimberly L. , Keswani, Rajesh N. , Kleinberg, Lawrence , Leong, Stephen , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Paluri, Ravi Kumar , Park, Haeseong , Poultsides, George A. , Roses, Robert E. , Strong, Vivian E. , Wiesner, Georgia L. , Willett, Christopher G. , Wright, Cameron D., McMillian, Nicole R., Pluchino, Lenora A. , Jaroszewski, Dawn, Ajani, Jaffer A , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Perry, Kyle A. , Pimiento, José M.
Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 855-883
Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.